Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells.

Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells.

A method for capturing material extracted from biochar, the method comprising the steps of: (i) providing a biochar; (ii) contacting the biochar with a treating liquid, where the treating liquid causes the removal of solids from the pores and surface of the biochar, thereby creating a resulting solution comprised of the treating liquid and removed solids; and (iii) collecting the resulting solution.

A method for capturing material extracted from biochar, the method comprising the steps of: (i) providing a biochar; (ii) contacting the biochar with a treating liquid, where the treating liquid causes the removal of solids from the pores and surface of the biochar, thereby creating a resulting solution comprised of the treating liquid and removed solids; and (iii) collecting the resulting solution.

Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.

Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

The invention relates to the medicine, namely to an agent for reducing the cholesterol and triglycerides in the blood plasma. The agent claimed comprises a nanocomposite that is a carbon-containing nanoparticles coated with the organic alkyl functional groups representing the residuals —C.sub.4H.sub.9, —C.sub.6H.sub.11, —C.sub.8H.sub.15, —C.sub.10H.sub.21, —C.sub.16H.sub.33, —C.sub.18H.sub.35. These groups are deposited by the covalent modification using diazonium salts of the general formula XC.sub.6H.sub.4N.sub.2.sup.+Y.sup.−, where X is the alkyl residual —C.sub.4H.sub.9, —C.sub.6H.sub.11, —C.sub.8H.sub.15, —C.sub.10H.sub.21, —C.sub.16H.sub.33, or C.sub.18H.sub.35, Y is the anion HSO.sub.4.sup.−, Cl.sup.−, BF.sub.4.sup.− or TsO.sup.−. The invention provides an effective reduction of cholesterol and triglyceride presented in the blood plasma.